On September
20, the U.S. FDA granted an accelerated approval to the antibody-drug conjugate
tisotumab vedotin for a subset of patients with recurrent or metastatic
cervical cancer. On September 29, it granted approval to the anti-EGFR antibody
cetuximab for a subset of patients with metastatic colorectal cancer. On
October 1, it approved the CAR T cell therapy brexucabtagene autoleucel for a
subset of patients with acute lymphoblastic leukemia.
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
No comments:
Post a Comment